99% Purity Raw Weight Loss Powder Rimonabant For Obesity Treatment
- Manufacturer: Dewael
- Product Assay: 99%+
- Appearance: White Powder.
- Place of Origin: China
- Certification: SGS,ISO9001,GMP
- Minimum Order Quantity: 10g
- Packaging Details: 1 kg/foil bag,25kg/drum or as your requirements
- Delivery Time: Within 12 hours after receiving your payment
- Payment Terms: Western Union, MoneyGram,Bitcoin,Bank Transfer
- Shipping: EMS,DHL,Fedex,UPS,TNT and so on.
- Policy: Re-Shipping Policy
- Supply ability: 500-600kg/month
99% Purity Raw Weight Loss Powder Rimonabant For Obesity Treatment
Details:
Product Name: Rimonabant
Synonyms: ACOMPLIA;RIMONABANT;RIMONABANT(ACOMPLIA,SR141716);5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-;5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;A 281;Sr 141716
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Assay 99%
Appearance: White Powder
Usage Weight loss powders/ Rimonabant is a selective antagonist
Product Categories: Weight Loss;SR141716
Rimonabant Specification:
Test Items | Specification | Test Results |
Description | White crystalline powder | White crystalline powder |
Identification | IR , UV conform | Conform |
Loss on drying | ≤0.5ml | 0.21ml |
Residue on ignition | Not more than 0.2% | 0.06ml |
Iron | Not more than 0.005% | 0.0018% |
Heavy metals | Not more than 0.001% | 0.0006% |
Related substances | Total: Not more than 1.0% Individual: Not more than 0.5% |
0.32% 0.14% |
E-isomer | Not more than 0.3% | 0.19% |
Organic volatile impurities | Conforms | Conforms |
Assay | 99.0~101.0% | 99.51% |
Conclusion | Conform with USP30 |
Rimonabant Description:
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities).Its main effect is reduction in appetite.
An experimental wonder drug, Rimonabant, helps you lose weight, quit smoking and it also helps protect your heart. Trials have shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years – this is a record, no other diet drug has managed to keep a person’s weight down for so long.
The second 33% lost 5% of body weight and kept it down. As well as keeping you lean, the drug also helps you quit the smoking habit. This will be of great interest for many smokers who are afraid to give up because they say they will put on loads of weight if they do.
Rimonabant Application:
Obesity:
Rimonabant is a weight loss drug, can significantly reduce weight, reduce waist circumference and reduce risk factors for cardiovascular disease, but also can improve blood lipids and insulin resistance and metabolic syndrome, especially for the presence of clinical obesity or heart disease people at risk.
Rimonabant as a new weight loss drug, can also be used to quit smoking. Not only lose weight, but also lower blood pressure, cholesterol and blood sugar, clinical study found that subjects taking one to two months later, the weight can be reduced on average six to eight kilograms.
Smoking cessation:
Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant “may increase the odds of quitting approximately 11/2-fold”.
Addiction behaviors:
Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans: priming and cues. It may also reduce ethanol- and opiate-seeking behavior.
———————————————————————————————————————————————————————————————————————————————————————-
Contact Now
Reviews
There are no reviews yet.